We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
Universal Health (UHS) remains well-poised for growth on growing patient volumes at its acute care and behavioral healthcare facilities, acquisitions and a commendable financial stand.
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
medical: Archive
New Strong Buy Stocks for March 19th
by Zacks Equity Research
AX, LI, GM, WILYY and DORM have been added to the Zacks Rank #1 (Strong Buy) List on March 19, 2024.
GMPositive Net Change DORMNegative Net Change WILYYPositive Net Change AXNegative Net Change LINegative Net Change
auto-tires-trucks finance medical
Here's Why You Should Retain Inspire Medical (INSP) Stock Now
by Zacks Equity Research
Inspire Medical's (INSP) focus on R&D raises optimism about the stock.
DVAPositive Net Change CAHNegative Net Change CORPositive Net Change INSPPositive Net Change
medical medical-devices
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
by Zacks Equity Research
Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
ACETNegative Net Change ADMANegative Net Change FGENPositive Net Change AQSTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Revvity's (RVTY) New Launch to Boost Newborn Sequencing Research
by Zacks Equity Research
Revvity's (RVTY) next-generation newborn sequencing research workflow is likely to build the foundation for diagnosing rare diseases in the future.
DVAPositive Net Change CAHNegative Net Change CORPositive Net Change RVTYNegative Net Change
medical medical-devices
Waters (WAT) Boosts PFAS Testing Solutions With New Cartridges
by Zacks Equity Research
Waters (WAT) launches Oasis WAX/GCB and GCB/WAX Cartridges for PFAS testing, thus boosting the Waters Operating segment.
DVAPositive Net Change WATNegative Net Change CAHNegative Net Change ICLRNegative Net Change
medical
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
by Zacks Equity Research
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
GSKNegative Net Change ANIPPositive Net Change ADMANegative Net Change IMRXPositive Net Change
biotechs medical
High Tide (HITI) Acquires Queen of Bud to Expand Its Portfolio
by Zacks Equity Research
High Tide (HITI) announces the acquisition of Queen of Bud to boost its in-house cannabis brand portfolio without burdening its significant capital expenditure.
DVAPositive Net Change CAHNegative Net Change CORPositive Net Change HITINegative Net Change
medical medical-devices
Here's Why You Should Retain Centene (CNC) Stock for Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
CIPositive Net Change CNCPositive Net Change ENSGNegative Net Change OGNNegative Net Change
medical
Chemed (CHE) Reaches a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.
SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change CHEPositive Net Change
medical medical-devices
Labcorp (LH) Presents New Research on Precision Diagnostics
by Zacks Equity Research
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
LHPositive Net Change SYKPositive Net Change CAHNegative Net Change CORPositive Net Change
medical medical-devices
Reasons to Retain DexCom (DXCM) Stock in Your Portfolio for Now
by Zacks Equity Research
DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.
DVAPositive Net Change CAHNegative Net Change DXCMPositive Net Change CORPositive Net Change
medical medical-devices
Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail
by Zacks Equity Research
Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.
BSXPositive Net Change SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change
medical
PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats
by Zacks Equity Research
PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.
SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change PETQNegative Net Change
medical
New Strong Sell Stocks for March 18th
by Zacks Equity Research
ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.
AMPHNegative Net Change ACNBNegative Net Change TRDANegative Net Change
biotechs finance medical
Do Options Traders Know Something About Gritstone bio (GRTS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Gritstone bio (GRTS) stock based on the movements in the options market lately.
GRTSPositive Net Change
medical
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Annovis Bio (ANVS) stock based on the movements in the options market lately.
ANVSPositive Net Change
medical
Company News for Mar 18, 2024
by Zacks Equity Research
Companies In The Article Are: GERN, AAPL, JBL and UBER
AAPLPositive Net Change GERNNegative Net Change JBLPositive Net Change UBERNegative Net Change
computers medical
Stock Market News for Mar 18, 2024
by Zacks Equity Research
Wall Street closed lwer on Friday with the Fed facing an inflation dilemma ahead of the policy meeting.
PHRNegative Net Change GCTNegative Net Change
business-services finance medical
Here's Why You Should Buy Insulet (PODD) Stock Right Now
by Zacks Equity Research
Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.
SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change PODDPositive Net Change
medical medical-devices
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
by Zacks Equity Research
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.
SYKPositive Net Change DVAPositive Net Change CAHNegative Net Change EXASPositive Net Change
medical medical-devices
Bear of the Day: AirSculpt (AIRS)
by David Bartosiak
Estimates have ticked on down for this year and next year though EPS growth remains.
APPPositive Net Change SQPositive Net Change AIRSNegative Net Change
medical
Should You Add Universal Health (UHS) to Your Portfolio?
by Zacks Equity Research
Universal Health (UHS) remains well-poised for growth on growing patient volumes at its acute care and behavioral healthcare facilities, acquisitions and a commendable financial stand.
UHSPositive Net Change HCAPositive Net Change LNTHNegative Net Change MEDPNegative Net Change
medical
Why Elevance (ELV) is a Smart Addition to Your Portfolio Now
by Zacks Equity Research
Elevance's (ELV) top line is poised to gain from rising product revenues, administrative fees and other revenues.
UHSPositive Net Change CIPositive Net Change HCATNegative Net Change ELVNegative Net Change
medical
Encompass Health (EHC) Up 42% in a Year: What Lies Ahead?
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of sustained top-line growth, an expanding healthcare facility portfolio and robust cash-generating abilities.
DXCMPositive Net Change ADUSPositive Net Change LMATNegative Net Change EHCPositive Net Change
medical
GE HealthCare (GEHC) Advances AI Alliance to Improve Workflow
by Zacks Equity Research
GE HealthCare's (GEHC) evolution of its AI collaboration is likely to lead to digital and AI transformation and provide better patient care and outcomes.
DVAPositive Net Change CAHNegative Net Change CORPositive Net Change GEHCPositive Net Change
medical medical-devices